Alglucosidase alfa drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.
The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.
Alglucosidase alfa drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.
The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.
Find and order your therapeutic molecules through smart filters
Up to 10 batches of original drugs for examining batch-to-batch variations
Up to 80% less compared to the original pharmaceutical price
Shipment within days worldwide according to GDP-standards
Up to 80% less compared to the original pharmaceutical price
Drug name | Myozyme® |
INN | Alglucosidase alfa |
API type | Enzyme |
Pharmacotherapeutic group | Other alimentary tract and metabolism products, enzymes |
ATC code | A16AB07 |
Target of antibody | Lysosomal glycogen |
General function | |
Short description | Alglucosidase alfa is indicated for long-term enzyme replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid α-glucosidase deficiency). Alglucosidase alfa is indicated in adults and paediatric patients of all ages. |
Pharmacodynamic properties (Mechanism of action; Source EMA document) | It is postulated that Myozyme will restore lysosomal GAA activity resulting in stabilisation or restoration of cardiac and skeletal muscle function (including respiratory muscles). Due to the blood-brain barrier effect and the enzyme’s size, uptake of alglucosidase alfa in the central nervous system is unlikely. |
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Pompe disease is a rare, progressive and fatal metabolic myopathy with an estimated global incidence of 1 in 40,000 births. Other names for Pompe disease include glycogen storage disease type II (GSD-II), acid maltase deficiency (AMD) and glycogenosis type II. Pompe disease belongs to the lysosomal storage disorders as it is caused by a deficiency of a naturally occurring lysosomal hydrolase, acid α-glucosidase (GAA) that degrades lysosomal glycogen to glucose. Deficiency of this enzyme leads to glycogen accumulation in various tissues, particularly cardiac, respiratory and skeletal muscle, leading to the development of hypertrophic cardiomyopathy and progressive muscle weakness, including impairment of respiratory function. |
Original license holder | Sanofi B.V. Paasheuvelweg 25 1105 BP Amsterdam The Netherlands |
Marketing authorisation numbers | EU/1/06/333/001-003 |
Marketing authorisation holder | Sanofi B.V. Paasheuvelweg 25 1105 BP Amsterdam The Netherlands |
Name of the manufacturer of the biological active substance | Genzyme Corporation 45, 51, 76, 74 and 80 New York Avenue, Framingham, MA 01701, United States Genzyme Flanders, Cipalstraat 8, 2440 Geel, Belgium |
Name and address of the manufacturer(s) responsible for batch release | Genzyme Ireland Limited, IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland |
Max shelf life | 3 years |
Storage conditions | 2°C – 8°C |
List of excipients | Mannitol (E421) Sodium dihydrogen phosphate monohydrate (E339) Disodium phosphate heptahydrate (E339) Polysorbate 80 (E433) |
Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany